EP0841910A4 - INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE - Google Patents

INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE

Info

Publication number
EP0841910A4
EP0841910A4 EP96925501A EP96925501A EP0841910A4 EP 0841910 A4 EP0841910 A4 EP 0841910A4 EP 96925501 A EP96925501 A EP 96925501A EP 96925501 A EP96925501 A EP 96925501A EP 0841910 A4 EP0841910 A4 EP 0841910A4
Authority
EP
European Patent Office
Prior art keywords
coa
apoptosis
inhibition
independent transacylase
transacylase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96925501A
Other languages
German (de)
English (en)
Other versions
EP0841910A1 (fr
Inventor
James David Winkler
Floyd Chilton Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0841910A1 publication Critical patent/EP0841910A1/fr
Publication of EP0841910A4 publication Critical patent/EP0841910A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96925501A 1995-07-25 1996-07-24 INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE Withdrawn EP0841910A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US223995P 1995-07-25 1995-07-25
US2239P 1995-07-25
PCT/US1996/012257 WO1997004765A1 (fr) 1995-07-25 1996-07-24 INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE

Publications (2)

Publication Number Publication Date
EP0841910A1 EP0841910A1 (fr) 1998-05-20
EP0841910A4 true EP0841910A4 (fr) 2006-09-13

Family

ID=21699854

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96925501A Withdrawn EP0841910A4 (fr) 1995-07-25 1996-07-24 INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE

Country Status (3)

Country Link
EP (1) EP0841910A4 (fr)
JP (1) JPH11511130A (fr)
WO (1) WO1997004765A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19829448A1 (de) * 1998-07-01 2000-10-12 Medmark Pharma Gmbh 1-Octadecyl-2-methyl-sn-glycero-3-phosphocholin (ET180CH3) zur Behandlung von humanen Mammakarzinomen
GB9904895D0 (en) * 1999-03-03 1999-04-28 Scarista Limited Regulators of coenzyme-A-independent transacylase as psychotropic drugs
UA93673C2 (ru) 2005-03-07 2011-03-10 Баер Шеринг Фарма Акциенгезельшафт Фармацевтическая композиция, которая содержит омега-карбоксиарилзамещенную дифенилмочевину, для лечения paka
EP2117555B1 (fr) * 2006-12-20 2012-10-17 Universitätsklinikum Hamburg-Eppendorf Utilisation d'un composé de glycérol tri-substitué dans le traitement des hémopathies malignes

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009590A1 (fr) * 1990-01-03 1991-07-11 Medmark Pharma Gmbh Composition pharmaceutique d'et18-och3 administrable par voie intraveineuse
WO1992004331A1 (fr) * 1990-09-11 1992-03-19 Smith Kline & French Laboratories Limited Derives de 2 imidazolones substitues, leur preparation et compositions pharmaceutiques
WO1993016674A1 (fr) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation INHIBITEURS DE LA CoA-IT ET DU PAF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470882A (en) * 1994-06-02 1995-11-28 Smithkline Beecham Corp. Anti-inflammatory compounds
US5545669A (en) * 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5447957A (en) * 1994-06-02 1995-09-05 Smithkline Beecham Corp. Anti-inflammatory compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009590A1 (fr) * 1990-01-03 1991-07-11 Medmark Pharma Gmbh Composition pharmaceutique d'et18-och3 administrable par voie intraveineuse
WO1992004331A1 (fr) * 1990-09-11 1992-03-19 Smith Kline & French Laboratories Limited Derives de 2 imidazolones substitues, leur preparation et compositions pharmaceutiques
WO1993016674A1 (fr) * 1992-02-11 1993-09-02 Smithkline Beecham Corporation INHIBITEURS DE LA CoA-IT ET DU PAF

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9704765A1 *

Also Published As

Publication number Publication date
EP0841910A1 (fr) 1998-05-20
WO1997004765A1 (fr) 1997-02-13
JPH11511130A (ja) 1999-09-28

Similar Documents

Publication Publication Date Title
PL327569A1 (en) Promedications of thrombosin inhibitors
IL118101A0 (en) Inhibitors of farnesyltransferase
EP1009415A4 (fr) INHIBITEURS DE $g(b)-LACTAMASES ET LEURS UTILISATIONS
GB9514437D0 (en) Inhibition of gene expression
ZA961600B (en) Inhibition of hair growth
PL322549A1 (en) Inhibitors of proteinous farnesiltransferase
SI1445259T1 (sl) Uporaba kristalnih oblik 2-metil-tienobenzodiazepina
GB9526560D0 (en) Use of 2-Amino-Heterocycles
GB9514435D0 (en) Inhibition of gene expression
ZA9610901B (en) Treatment and prophylaxis of osteoporosis
AU6692996A (en) Inhibitors of apoptosis
EP0711168A4 (fr) Procedes de traitement de l'apoptose et d'etats associes
ZA9610798B (en) Inhibitors of interleuken-1beta converting enzyme
IL123320A0 (en) Detection of hypoprathyroidism
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
EP0830375A4 (fr) Inhibiteur humain du gene 1 de l'apoptose
IL118574A0 (en) Methods of inhibiting melanoma
HUP9603529A2 (en) Femoral part of hip-joint-prothesis
GB9621852D0 (en) Inhibition of scale
PL320114A1 (en) Phenyl-substituted fluoroderivatives of 4-azasteroides
EP0841910A4 (fr) INHIBITION D'UNE TRANSACYLASE INDEPENDANTE DE LA COENZYME A (CoA) ET APOPTOSE
IL114831A0 (en) Determination of chromium
ZA969429B (en) Amidinohydrazones of ketones
GB9526691D0 (en) Medical use of proteases
EP0833668A4 (fr) Inhibition de la replication du virus de l'hepatite b

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

A4 Supplementary search report drawn up and despatched

Effective date: 20060817

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061117